CYVNY

Ceryvyn Therapeutics Limited, formerly Opthea Limited, is an Australia-based clinical-stage biopharmaceutical company. The Company is focusing on developing therapies by translating advances in human biology into transformative medicines for patients with serious diseases. It focuses on identifying biological mechanisms that drive disease and developing targeted therapies capable of addressing unmet medical needs. Its focus is lymphangioleiomyomatosis (LAM), a rare, chronic and progressive systemic disease that predominantly affects women and primarily involves the lungs, where it leads to progressive loss of lung function. The Company's lead development program, CYV-101, is a fusion protein designed to selectively bind and neutralize VEGF-C and VEGF-D, key signaling proteins involved in pathological lymphangiogenesis. It targets a fundamental biological pathway to drive disease progression, CYV-101 offers a differentiated therapeutic approach for patients with LAM.